Prospective, multicenter, randomized GITMO-IIL trial comparing intensive (R-HDS) to conventional chemoimmunotherapy (CHOP-R) in high-risk follicular lymphoma (FL) at diagnosis
Marco Ladetto(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Corrado Tarella(European Institute of Oncology), Paolo Corradini(Gruppo di Ricerca Geriatrica), Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Fabio Benedetti(Azienda Ospedaliera Universitaria Integrata Verona), Caterina Patti(Ospedale Vincenzo Cervello), Roberto Passera(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Umberto Vitolo(Candiolo Cancer Institute), A. M. Gianni(Azienda Ospedaliero Universitaria San Giovanni Battista), F. De Marco(Azienda Ospedaliero Universitaria San Giovanni Battista)
Cited by 2
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|920